Akeso Bio (Cayman Islands) Limited (Akeso Bio) submitted the latest Securities Change Monthly Report to Hong Kong Exchanges and Clearing Limited on October 3, 2024, reporting the share changes as of September 30, 2024. The report shows that the company's statutory/registered share capital and issued shares (excluding treasury shares) remained unchanged during the reporting period, staying at 5,000,000,000 ordinary shares with a par value of $0.00001 per share, totaling $50,000 in registered share capital, and the total number of issued shares is 865,857,176 shares. In addition, the company's share options plan was amended on June 30, 2024, with no share options exercised, canceled, or expired within this month, and the remaining share options number remained at 394,000 shares. There were no changes in the company's post-initial public offering share purchase rights plan and restricted share unit plan. Overall, there were no increases or decreases in the company's issued shares and treasury shares this month.

Akeso Bio (Cayman Islands) Limited (Akeso Bio) submitted the latest Securities Change Monthly Report to Hong Kong Exchanges and Clearing Limited on October 3, 2024, reporting the share changes as of September 30, 2024. The report shows that the company's statutory/registered share capital and issued shares (excluding treasury shares) remained unchanged during the reporting period, staying at 5,000,000,000 ordinary shares with a par value of $0.00001 per share, totaling $50,000 in registered share capital, and the total number of issued shares is 865,857,176 shares. In addition, the company's share options plan was amended on June 30, 2024, with no share options exercised, canceled, or expired within this month, and the remaining share options number remained at 394,000 shares. There were no changes in the company's post-initial public offering share purchase rights plan and restricted share unit plan. Overall, there were no increases or decreases in the company's issued shares and treasury shares this month.